Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00104169
Status:
TERMINATED
Last Update Posted:
2008-08-29
First Post:
2005-02-23
Brief Title:
Idiopathic Anemia of Aging IAA
Sponsor:
National Institute on Aging NIA
Organization:
National Institute on Aging NIA
Study Overview
Official Title:
Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging IAA
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No subject accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to examine whether Epoetin Alfa a hormone stimulating production of red blood cells can reverse idiopathic anemia
Detailed Description:
As individuals become older the frequency of anemia increases While the cause of anemia in many cases can be determined and corrected in a number of individuals there is no correctable cause found and the patient must live with their anemia This is known as idiopathic anemia and can have serious consequences for the individual Numerous studies have demonstrated that anemia is associated with loss of energy and stamina causing individuals to decrease their activities which adversely affects both their sense of well-being as well as their physical strength Losses in these areas are associated with the clinical manifestations of frailty
The current pilot study will examine whether or not administration of Epoetin Alfa a hormone stimulating production of red blood cells can reverse this type of anemia We will examine the consequences of reversing the anemia in terms of physical strength and function cardiovascular function and sense of well-being and mental function
In this study individuals with anemia will be treated for six months with Epoetin Alfa following the correction of their anemia and measurements done to evaluate physical strength performance cardiac mental and kidney function At the end of treatment individuals will be followed for an additional six months to determine whether the anemia recurs and physical function decreases
Participation in this study is voluntary All testing and medication received are free to the participant
The current pilot study will examine whether or not administration of Epoetin Alfa a hormone stimulating production of red blood cells can reverse this type of anemia We will examine the consequences of reversing the anemia in terms of physical strength and function cardiovascular function and sense of well-being and mental function
In this study individuals with anemia will be treated for six months with Epoetin Alfa following the correction of their anemia and measurements done to evaluate physical strength performance cardiac mental and kidney function At the end of treatment individuals will be followed for an additional six months to determine whether the anemia recurs and physical function decreases
Participation in this study is voluntary All testing and medication received are free to the participant
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None